Skip to content

Controversial Reversal? Let's Talk DOACs

Anticoagulation is a pillar of treatment for thrombosis and various disorders resulting in thromboembolic complications, such as atrial fibrillation. However, direct oral anticoagulants (DOACS) contribute to subsequent increased morbidity and mortality from bleeds. This CE will educate pharmacists on the reversal agents for DOACs, which aid in the management of major bleeds complicated by DOAC use. Pharmacists will be introduced to appropriate anticoagulant reversal strategies based on the available expert consensus reports and published primary literature.

Learning Objectives

Upon completion of this activity, the participant will be able to:

  • Explain the mechanism of action of DOAC reversal agents.
  • Identify contraindications for therapy with reversal agents.
  • Describe key points published within current literature to support recommendations for reversal agents.
  • Construct a treatment plan for DOAC reversal patients in patients presenting with a major bleed.

Presenter

Jennifer Hammond, PharmD, is a PGY1 pharmacy resident at Baystate Medical Center in Springfield, Massachusetts. She obtained her Doctor of Pharmacy degree in May 2021 from the University of New England School of Pharmacy in Portland, Maine. Jennifer’s practice interests include critical care and emergency medicine.

Registration Fee: This module is provided free of charge.

Register


Release Date: June 9, 2022
Expiration Date: June 9, 2023
ACPE UAN: 0026-0000-22-130-H01-P | Knowledge
Topic Designator: Disease State Management/Drug Therapy
Contact Hours:
1 (0. 1 CEU)

Accreditation

ACPE logo

Massachusetts College of Pharmacy and Health Sciences is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Massachusetts College of Pharmacy and Health Sciences designates this activity for a total of 1 contact hour (0.1 CEU).

Requirements for Credit

In order to receive credit, the participant must view the entire presentation and complete the pre and post-tests, and evaluation form. Upon completion, participant credit will be reported to CPE Monitor. Transcripts may be printed from CPE Monitor.

Statement of Disclosure

Massachusetts College of Pharmacy and Health Sciences adheres to the ACPE Standards for Integrity and Independence in Continuing Education. It is the policy of MCPHS that the speakers and planning committee members disclose all financial relationships with ineligible companies within the last 24 months, and that relevant conflicts of interest are mitigated. Speakers will disclose any off-label/unapproved use of drugs or devices during their presentation.

Jennifer Hammond has no relevant financial relationships with ineligible companies to disclose.

Residency Director Frank Szczerba has no relevant financial relationships with ineligible companies to disclose.

Massachusetts College of Pharmacy and Health Sciences Continuing Education staff members hold no financial relationships with ineligible companies, related to the content of this presentation.

Off-label/investigational uses of Prothrombin Complex Concentrate (human) will be discussed.

No funding from industry provided for this event. No exhibitors will be present